Ask about this productRelated genes to: TMEM108 Blocking Peptide
- Gene:
- TMEM108 NIH gene
- Name:
- transmembrane protein 108
- Previous symbol:
- -
- Synonyms:
- MGC3040, CT124
- Chromosome:
- 3q22.1
- Locus Type:
- gene with protein product
- Date approved:
- 2005-12-22
- Date modifiied:
- 2014-11-18
Related products to: TMEM108 Blocking Peptide
Related articles to: TMEM108 Blocking Peptide
- Progression from Parkinson's disease (PD) to Lewy body dementia is a major clinical concern. Although several progression-associated loci have been identified, their cumulative effects on cognitive decline have not been systematically evaluated. To assess the dose-dependent effect of five candidate progression loci linked to synaptic vulnerability (RIMS2, TMEM108, GBA1) and amyloid-tau pathology (APOE, WWOX), we analyzed 7745 participants from 24 cohorts with 28,737 longitudinal visits over 15 years using random-effects meta-analyses of cohort-specific Cox proportional hazards models. Dementia risk increased monotonically with the number of progression loci (0, 1, 2, or ≥3). A single locus conferred a 1.56-fold increase in risk (hazard ratio (HR) = 1.56, 95% CI: 1.28-1.89), rising to 3.21-fold for two loci (HR = 3.21, 95% CI: 2.19-4.70) and 7.49-fold for three or more loci (HR = 7.49, 95% CI: 4.98-11.28). Individually, GBA1 (HR = 2.09), APOE ε4 (HR = 1.71), RIMS2 (HR = 1.90), TMEM108 (HR = 2.05), and WWOX (HR = 1.56) were associated with dementia risk, but there was heterogeneity between clinical trials, biomarkers, and population-based cohorts. Multi-locus dosage increases dementia risk in a monotonic manner and may improve stratification and clinical trial design in PD. - Source: PubMed
Publication date: 2026/05/14
Kang XiaoyingLin ZechuanCalikusu Fatma ZehraMiller Lauren ASoriano SofiaLocascio Joseph JCorvol Jean-ChristopheMaple-Grødem JodiFan YangyiMead KaraCampbell Meghan CElbaz AlexisLesage SuzanneBrice AlexisHung Albert YSchwarzschild Michael AHayes Michael TWills Anne-MarieHerrington Todd MLiu GanqiangRavina BernardTaba PilleKõks SulevSimuni TanyaForsgren LarsCounsell CarlMacleod Angus DBeach Thomas GAlves GuidoTysnes Ole-BjørnPerlmutter Joel SHeutink PeterKasten MeikeMollenhauer BritTrenkwalder ClaudiaKlein ChristineHepp Dagmar HBackstrom DavidSvenningsson PerHu Michele TWilliams-Gray Caroline HBarker Roger A Scherzer Clemens R - Colon cancer is a leading global malignancy with significant health burden. As key regulators of tumorigenesis, microRNAs (miRNAs) are implicated in colon cancer progression, yet the role of miR-1303-its clinical significance and molecular mechanism-remains unclear. This study aimed to investigate the regulatory effects of miR-1303 and validate its potential as an independent prognostic indicator. miR-1303 expression was analyzed qRT-PCR in 117 paired CRC tissues and adjacent normal tissues. Clinical relevance was evaluated Kaplan-Meier survival curves and Cox proportional hazards modeling. Functional assays (CCK-8, Transwell migration/invasion, luciferase reporter) were performed in SW480 and HCT116 cells. Target genes were predicted using miRDB and TargetScan. Rescue experiments confirmed miR-1303 regulates CRC progression by targeting TMEM108. miR-1303 was significantly upregulated in colon cancer tissues compared to normal tissues ( < 0.001) and correlated with advanced TNM stage ( = 0.021), lymph node metastasis ( = 0.005), poor differentiation ( = 0.031), and larger tumor size ( = 0.044). High miR-1303 expression predicted poorer overall survival ( = 0.001) and was recognized as an independent predictor of prognosis (HR = 2.096, 95% CI = 1.080-4.071). Functional studies revealed that miR-1303 inhibition suppressed colon cancer cell proliferation, migration, and invasion. Mechanistically, miR-1303 directly targeted the TMEM108, leading to its post-transcriptional repression. Upregulated miR-1303 in colon cancer served as a poor prognosis predictor. miR-1303 promotes tumor progression in colon cancer by targeting TMEM108. - Source: PubMed
Publication date: 2025/09/24
Cheng QuanFu Huazhou - Prostate cancer (PCa) is a leading cause of cancer-related death in men. Understanding the proteomic landscape associated with PCa risk can provide insights into its molecular mechanisms and pave the way for potential therapeutic interventions. - Source: PubMed
Publication date: 2024/07/27
Sun WenguoLi HaomingShi WenjieLv QuanlongZhang Weili - Cancer testis antigens (CTAs) are a class of immune-stimulating antigens often overexpressed in many types of cancers. The usage of the CTAs as immunotherapy targets have been widely investigated in different cancers including melanoma, hematological malignancies, and colorectal cancer. Studies have indicated that the epigenetic regulation of the CTAs such as the methylation status may affect the expression of the CTAs. However, the report on the methylation status of the CTAs is conflicting. The general methylation profile of the CTAs, especially in colorectal cancer, is still elusive. - Source: PubMed
Abu NadiahRus Bakarurraini Nurul Ainaa AdilahNasir Siti NurmiIshak MuhiddinBaharuddin RashidahJamal RahmanAb Mutalib Nurul Syakima - Parkinson's disease (PD) is a neurodegenerative disorder with the manifestation of motor symptoms and non-motor symptoms. Previous studies have indicated the role of several transmembrane (TMEM) protein family genes in PD pathogenesis. - Source: PubMed
Publication date: 2022/07/04
Zhao YuwenZhang KailinPan HongxuWang YigeZhou XiaoxiaXiang YaqinXu QianSun QiyingTan JieqiongYan XinxiangLi JinchenGuo JifengTang BeishaLiu Zhenhua